Results 111 to 120 of about 22,784 (283)

New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin

Diabetes, Metabolic Syndrome and Obesity, 2010
Baptist GallwitzDept Medicine IV, Tübingen University, Otfried-Müller-Str, 10, 72076 Tübingen, GermanyAbstract: Saxagliptin is a novel dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor) for the treatment of type 2 diabetes, with a duration
Gallwitz B
doaj   +2 more sources

Mechanism of Action of Natural Dipeptidyl Peptidase-IV Inhibitors (Berberine and Mangiferin) in Experimentally Induced Diabetes with Metabolic Syndrome. [PDF]

Int J Appl Basic Med Res, 2023
Suman RK, Borde MK, Mohanty IR, Singh HK.   +3 more
europepmc   +1 more source

The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies

Clinical Pharmacology: Advances and Applications, 2016
Melanie Davies,1,2 Sudesna Chatterjee,1,2 Kamlesh Khunti1,2 1Diabetes Research Centre, University of Leicester, 2Leicester Diabetes Centre, University Hospitals of Leicester NHS Trust, Leicester, UK Abstract: Worldwide, an estimated 200 million people ...
Davies M, Chatterjee S, Khunti K
doaj  

Changes in gastrointestinal motility and gut hormone secretion after Roux‐en‐Y gastric bypass and sleeve gastrectomy for individuals with severe obesity

Clinical Obesity, Volume 15, Issue 2, April 2025.
Summary Background Bariatric surgery is very effective in long‐term weight management. The present study was undertaken to investigate the short‐term effects of sleeve gastrectomy (SG) and of Roux‐en‐Y gastric bypass (RYGB) on (a) gastrointestinal (GI) motility, that is gastric emptying and oro‐cecal transit time and (b) secretion of regulatory gut ...
Jennifer A. Wilbrink, Mark van Avesaat, Simon W. Nienhuijs, Arnold Stronkhorst, Ad A. M. Masclee   +4 more
wiley   +1 more source

Determinants of Glycemic Response to Add-On Therapy with a Dipeptidyl Peptidase-4 Inhibitor: A Retrospective Cohort Study Using a United Kingdom Primary Care Database. [PDF]

, 2016
BACKGROUND: Apart from baseline glycated hemoglobin (HbA1c), little is known about clinical parameters that affect glycemic response to a dipeptidyl peptidase-4 (DPP4) inhibitor when used in routine clinical practice. We aimed to use a large primary care
Donnelly, Richard, Idris, Iskandar, Mamza, Jil, Mehta, Rajnikant   +3 more
core   +1 more source

Work productivity, associated risk factors and costs on presenteeism and absenteeism in Chinese patients with young‐onset type‐2 diabetes in Hong Kong

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Those with young‐onset type‐2 diabetes (YOD), diagnosed before age of 40 years, experience heightened risk of complications. The economic burden extends beyond medical costs, impacting work productivity. Materials and Methods Chinese patients with YOD were recruited between June 2023 and April 2024 in the Precision Medicine to redefine ...
Juliana N. M. Lui, Kelly T. C. Wong, Eric S. H. Lau, Sunny C. S. Chan, Nga Sze Wong, Jenny Y. Z. Zhang, Kit Ming Wai, Chun Kwan O, Baoqi Fan, Hongjiang Wu, Ronald C. W. Ma, Alice P. S. Kong, Andrea O. Y. Luk, Elaine Y. K. Chow, Juliana C. N. Chan   +14 more
wiley   +1 more source

Heterocyclic Compounds as Dipeptidyl Peptidase-IV Inhibitors with Special Emphasis on Oxadiazoles as Potent Anti-Diabetic Agents. [PDF]

Molecules, 2022
Mohammad BD, Baig MS, Bhandari N, Siddiqui FA, Khan SL, Ahmad Z, Khan FS, Tagde P, Jeandet P.   +8 more
europepmc   +1 more source

Circulating MicroRNAs in Elderly Type 2 Diabetic Patients [PDF]

, 2018
The circulating microRNAs (miRNAs) associated with type 2 diabetes (T2D) in elderly patients are still being defined. To identify novel miRNA biomarker candidates for monitoring responses to sitagliptin in such patients, we prospectively studied 40 T2D ...
Abballe, Luana, Besharat, Zein Mersini, Borgiani, Paola, Catanzaro, Giuseppina, Chiacchiarini, Martina, Dotta, Francesco, Ferretti, Elisabetta, Po, Agnese, Sabato, Claudia, Tesauro, Manfredi, Vacca, Alessandra   +10 more
core   +3 more sources

Literature‐informed ensemble machine learning for three‐year diabetic kidney disease risk prediction in type 2 diabetes: Development, validation, and deployment of the PSMMC NephraRisk model

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Introduction Diabetic kidney disease (DKD) and diabetic nephropathy (DN) affect around 40% of diabetic patients but lack accurate risk prediction tools that include social determinants and demographic complexity. We developed and validated an ensemble machine learning model for three‐year DKD/DN risk prediction with deployment readiness ...
Ayla M. Tourkmani, Turki J. Al‐Harbi, Ahmad Abdullah Alghamdi, Ibrahim M. Youzghadli, Faris Saad Alosaimi, Ahmed Y. Azzam   +5 more
wiley   +1 more source

Suspected adverse drug reactions of the type 2 antidiabetic drug class dipeptidyl-peptidase IV inhibitors (DPP4i): Can polypharmacology help explain? [PDF]

Pharmacol Res Perspect, 2022
Jones L, Jones AM.
europepmc   +1 more source